Showing 5981-5990 of 7756 results for "".
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- Can Softening Stem Cells Coax Hair Growth in Aging Hair? Maybehttps://practicaldermatology.com/news/can-softening-stem-cells-coax-hair-growth-in-aging-hair/2461761/Hair follicle stem cells get stiff with age, making it harder for them to grow hair, but if the hair follicle’s stem cells are softened, they are more likely to produce hair, new research suggests. In a study in mice
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is bei
- Castle Biosciences Gives Back for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-gives-back-for-skin-cancer-awareness-month/2461750/Castle Biosciences, Inc. is teaming up with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education and advocacy. “At our core, we are passionate about transforming disease management, improving health and making a meaningful difference in
- Survey Highlights Room for Improvement in AK Awarenesshttps://practicaldermatology.com/news/survey-highlights-room-for-improvement-in-ak-awareness/2461746/As many as 85% of people are unaware of actinic keratosis (AK), according to a new survey from Almirall. The survey of more than 2,500 participants over the age or 35 aimed to understand the level of knowledge about AK and skin health habits within the general population of Spain, Germa
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese p
- Almirall, CRG Partner to Develop Novel Preclinical Models for NMSChttps://practicaldermatology.com/news/almirall-crg-partner-to-develop-novel-preclinical-models-for-nmsc/2461741/Almirall and the Centre for Genomic Regulation (CRG) are joining forces to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC). This partnership, led by Almirall's investigators Dr
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven